# BEFORE THE BOARD OF PHARMACY DEPARTMENT OF CONSUMER AFFAIRS STATE OF CALIFORNIA

In the Matter of the Accusation Against:

# GARFIELD BEACH CVS, LLC dba CVS PHARMACY #2994, Respondent

### Pharmacy Permit No. PHY 50132

## Agency Case No. 6743

### **DECISION AND ORDER**

The attached Stipulated Settlement and Disciplinary Order for Public Reproval is hereby

adopted by the Board of Pharmacy, Department of Consumer Affairs, as its Decision in this

matter.

This Decision shall become effective at 5:00 p.m. on November 25, 2020.

It is so ORDERED on October 26, 2020.

BOARD OF PHARMACY DEPARTMENT OF CONSUMER AFFAIRS STATE OF CALIFORNIA

My n. Lippe

By

Greg Lippe Board President

1	XAVIER BECERRA	
2	Attorney General of California KAREN R. DENVIR	
3	Supervising Deputy Attorney General KRISTINA T. JARVIS	
4	Deputy Attorney General State Bar No. 258229	
5	1300 I Street, Suite 125 P.O. Box 944255	
6	Sacramento, CA 94244-2550 Telephone: (916) 210-6088	
7	Facsimile:(916)327-8643Attorneys for Complainant	
8		
9	BEFOR BOARD OF H	
10	DEPARTMENT OF C STATE OF C	
11	STATE OF C	
12	In the Matter of the Accusation Against:	Case No. 6743
13	GARFIELD BEACH CVS, LLC DBA CVS PHARMACY #2994	STIPULATED SETTLEMENT AND DISCIPLINARY ORDER FOR PUBLIC
14	3100 Geer Road Turlock, CA 95382	REPROVAL
15	Pharmacy Permit No. PHY 50132	[Bus. & Prof. Code § 495]
16	Respondent.	
17		
18		
19		EED by and between the parties to the above-
20	entitled proceedings that the following matters are	
21	PAR	
22		Executive Officer of the Board of Pharmacy
23	(Board). She brought this action solely in her off	
24	Xavier Becerra, Attorney General of the State of	California, by Kristina T. Jarvis, Deputy
25	Attorney General.	
26		C, doing business as (dba) CVS Pharmacy #2994
27	(Respondent) is represented in this proceeding by	attorney Jeff J. Astarabadi, Much Shelist, P.C.,
28	2 Park Plaza, Suite 1075, Irvine, CA 92614.	
		1
	STIP SETTLEMEN	VT & DISC ORDER FOR PUBLIC REPROVAL (6743)

1	3. On or about October 23, 2009, the Board issued Pharmacy Permit No. PHY 50132 to
2	Garfield Beach CVS LLC, dba CVS Pharmacy #2994 (Respondent). The Pharmacy Permit was
3	in full force and effect at all times relevant to the charges brought in Accusation No. 6743 and
4	will expire on June 1, 2021, unless renewed.
5	JURISDICTION
6	4. Accusation No. 6743 was filed before the Board and is currently pending against
7	Respondent. The Accusation and all other statutorily required documents were properly served
8	on Respondent on November 5, 2019. Respondent timely filed its Notice of Defense contesting
9	the Accusation. A copy of Accusation No. 6743 is attached as exhibit A and incorporated herein
10	by reference.
11	ADVISEMENT AND WAIVERS
12	5. Respondent has carefully read, fully discussed with counsel, and understands the
13	charges and allegations in Accusation No. 6743. Respondent has also carefully read, fully
14	discussed with counsel, and understands the effects of this Stipulated Settlement and Disciplinary
15	Order for Public Reproval.
16	6. Respondent is fully aware of its legal rights in this matter, including the right to a
17	hearing on the charges and allegations in the Accusation; the right to be represented by counsel at
18	its own expense; the right to confront and cross-examine the witnesses against them; the right to
19	present evidence and to testify on its own behalf; the right to the issuance of subpoenas to compel
20	the attendance of witnesses and the production of documents; the right to reconsideration and
21	court review of an adverse decision; and all other rights accorded by the California
22	Administrative Procedure Act and other applicable laws.
23	7. Respondent voluntarily, knowingly, and intelligently waives and gives up each and
24	every right set forth above.
25	<u>CULPABILITY</u>
26	8. Respondent understands and agrees that the charges and allegations in Accusation
27	No. 6743, if proven at a hearing, constitute cause for imposing discipline upon its Pharmacy
28	Permit.
	2
	STIP SETTLEMENT & DISC ORDER FOR PUBLIC REPROVAL (6743)

9. For the purpose of resolving the Accusation without the expense and uncertainty of 1 2 further proceedings, Respondent agrees that, at a hearing, Complainant could establish a factual basis for the charges in the Accusation, and that Respondent hereby gives up its right to contest 3 those charges. 4

10. Respondent agrees that its Pharmacy Permit is subject to discipline and they agree to 5 be bound by the Disciplinary Order below. 6

7

#### CONTINGENCY

11. This stipulation shall be subject to approval by the Board of Pharmacy. Respondent 8 understands and agrees that counsel for Complainant and the staff of the Board of Pharmacy may 9 communicate directly with the Board regarding this stipulation and settlement, without notice to 10 or participation by Respondent or its counsel. By signing the stipulation, Respondent understands 11 and agrees that they may not withdraw its agreement or seek to rescind the stipulation prior to the 12 time the Board considers and acts upon it. If the Board fails to adopt this stipulation as its 13 Decision and Order, the Stipulated Settlement and Disciplinary Order for Public Reproval shall 14 be of no force or effect, except for this paragraph, it shall be inadmissible in any legal action 15 between the parties, and the Board shall not be disqualified from further action by having 16 considered this matter. 17

18

12. The parties understand and agree that Portable Document Format (PDF) and facsimile copies of this Stipulated Settlement and Disciplinary Order for Public Reproval, including PDF 19 and facsimile signatures thereto, shall have the same force and effect as the originals. 20

This Stipulated Settlement and Disciplinary Order for Public Reproval is intended by 21 13. the parties to be an integrated writing representing the complete, final, and exclusive embodiment 22 of their agreement. It supersedes any and all prior or contemporaneous agreements, 23

24 understandings, discussions, negotiations, and commitments (written or oral). This Stipulated Settlement and Disciplinary Order for Public Reproval may not be altered, amended, modified, 25

supplemented, or otherwise changed except by a writing executed by an authorized representative 26 of each of the parties. 27

28

///

14.	In consideration of the foregoing admissions and stipulations, the parties agree that
the Board	may, without further notice or formal proceeding, issue and enter the following
Disciplina	ry Order:

#### **DISCIPLINARY ORDER**

IT IS HEREBY ORDERED that Pharmacy Permit No. PHY 50132 issued to Respondent Garfield Beach CVS, LLC dba CVS Pharmacy #2994 (Respondent) shall be publicly reproved by the Board of Pharmacy under Business and Professions Code section 495 in resolution of Accusation No. 6743, attached as exhibit A.

9 The Board of Pharmacy expresses its disapproval specifically for the issues underlying this 10 case; to wit, Respondent's management and treatment of "floating" licensed staff members, both 11 pharmacist and pharmacy technician, and Respondent's lack of oversight and supervision of such 12 staff that allowed such thefts to be possible.

Cost Recovery. Respondent shall pay \$4,795.00 to the Board for its costs associated with the investigation and enforcement of this matter. Respondent shall be permitted to pay these costs in a payment plan approved by the Board. If Respondent fails to pay the Board costs as ordered, Respondent shall not be allowed to renew their Pharmacy Permit until Respondent pays costs in full.

18

1

2

3

4

5

6

7

8

### **ACCEPTANCE**

I have carefully read the above Stipulated Settlement and Disciplinary Order for Public
Reproval and have fully discussed it with my attorney, Jeff J. Astarabadi. I understand the
stipulation and the effect it will have on my Pharmacy Permit. I enter into this Stipulated
Settlement and Disciplinary Order for Public Reproval voluntarily, knowingly, and intelligently,
and agree to be bound by the Decision and Order of the Board of Pharmacy.

25 DATED:

///

26 27

24

28

GARFIELD BEACH CVS, LLC dba CVS PHARMACY #2994 Respondent

.1.	14. In consideration of the foregoing admissions and stipulations, the parties agree that
2	the Board may, without further notice or formal proceeding, issue and enter the following
3	Disciplinary Order:
4	DISCIPLINARY ORDER
5	IT IS HEREBY ORDERED that Pharmacy Permit No. PHY 50132 issued to Respondent
6	Garfield Beach CVS, LLC dba CVS Pharmacy #2994 (Respondent) shall be publicly reproved by
7	the Board of Pharmacy under Business and Professions Code section 495 in resolution of
8	Accusation No. 6743, attached as exhibit A.
9	The Board of Pharmacy expresses its disapproval specifically for the issues underlying this
10	case; to wit, Respondent's management and treatment of "floating" licensed staff members, both
11	pharmacist and pharmacy technician, and Respondent's lack of oversight and supervision of such
12	staff that allowed such thefts to be possible.
13	Cost Recovery. Respondent shall pay \$4,795.00 to the Board for its costs associated with
14	the investigation and enforcement of this matter. Respondent shall be permitted to pay these
15	costs in a payment plan approved by the Board. If Respondent fails to pay the Board costs as
16	ordered, Respondent shall not be allowed to renew their Pharmacy Permit until Respondent pays
17	costs in full.
18	ACCEPTANCE
19	I have carefully read the above Stipulated Settlement and Disciplinary Order for Public
20	Reproval and have fully discussed it with my attorney, Jeff J. Astarabadi. I understand the
21	stipulation and the effect it will have on my Pharmacy Permit. I enter into this Stipulated
22	Settlement and Disciplinary Order for Public Reproval voluntarily, knowingly, and intelligently,
23	and agree to be bound by the Decision and Order of the Board of Pharmacy.
24	
25	DATED: 8/11/2020 200 200
26	GARFIELD BEACH CVS, LLC dba CVS PHARMACY #2994
27	Respondent
28	///
	4

1	I have read and fully discussed with Respondent CVS Pharmacy #2994 the terms and
2	conditions and other matters contained in the above Stipulated Settlement and Disciplinary Order
3	for Public Reproval. I approve its form and content.
4	
5	DATED: 812
6	JEFF J. ASTARABADI Attorney for Respondent
7	
8	
9	ENDORSEMENT
10	The foregoing Stipulated Settlement and Disciplinary Order for Public Reproval is hereby
11	respectfully submitted for consideration by the Board of Pharmacy of the Department of
12	Consumer Affairs.
13	DATED: Respectfully submitted,
14	XAVIER BECERRA Attorney General of California
15	Attorney General of California KAREN R. DENVIR Supervising Deputy Attorney General
16	Supervising Deputy Attorney General
17	
18	KRISTINA T. JARVIS Deputy Attorney General Attorneys for Complainant
19	Attorneys for Complainant
20	
21	
22	
23	
24	
25	
26	
27	SA2019103159
28	34202674.docx
	5 STIP SETTI EMENT & DISC ORDER FOR PLIET IC REPROVAT (67/3)

1	I have read and fully discussed with Respondent CVS Pharmacy #2994 the terms and
2	conditions and other matters contained in the above Stipulated Settlement and Disciplinary Order
3	for Public Reproval. I approve its form and content.
4	
5	DATED:
6	JEFF J. ASTARABADI Attorney for Respondent
7	nitorney for respondent
8	
9	<u>ENDORSEMENT</u>
10	The foregoing Stipulated Settlement and Disciplinary Order for Public Reproval is hereby
11	respectfully submitted for consideration by the Board of Pharmacy of the Department of
12	Consumer Affairs.
13	DATED: <u>9/24/2020</u> Respectfully submitted,
14	XAVIER BECERRA
15	Attorney General of California KAREN R. DENVIR Supervising Deputy Attorney General
16	
17	Brustin Junio
18	KRISTINA TŒARVIS Deputy Attorney General
19	Attorneys for Complainant
20	
21	
22	
23	
24	
25	
26	
27	SA2019103159
28	34202674.docx
	5 STIP SETTLEMENT & DISC ORDER FOR PUBLIC REPROVAL (6743)

## Exhibit A

Accusation No. 6743

1	XAVIER BECERRA	
2	Attorney General of California KENT D. HARRIS	
3	Supervising Deputy Attorney General MABEL LEW	
4	Deputy Attorney General State Bar No. 158042	
5	1300 I Street, Suite 125 P.O. Box 944255	
6	Sacramento, CA 94244-2550 Telephone: (916) 210-6104	
7	Facsimile: (916) 327-8643 Attorneys for Complainant	
8		FORE THE
9		OF PHARMACY DF CONSUMER AFFAIRS
10	STATE (	OF CALIFORNIA
11		1
12	In the Matter of the Accusation Against:	Case No. 6743
13	GARFIELD BEACH CVS, LLC DBA CVS PHARMACY # 2994	
14	3100 Geer Road Turlock, CA 95382	ACCUSATION
15	Pharmacy Permit No. PHY 50132	
16	Respondent.	
17		
18	Complainant alleges:	
19	<u>]</u>	PARTIES
20	1. Anne Sodergren ("Complainant"	) brings this Accusation solely in her official
21	capacity as the Interim Executive Officer of	the Board of Pharmacy ("Board"), Department of
22	Consumer Affairs.	
23	2. On or about October 23, 2009, the	he Board issued Original Permit Number PHY 50132
24	to Garfield Beach CVS, LLC, to do business	as CVS Pharmacy # 2994 ("Respondent"), which is
25 26	located at 3100 Geer Road, Turlock, Californ	nia. The pharmacy permit was in full force and effect
26 27	at all times relevant to the charges brought in	n the Accusation and will expire on June 1, 2020,
27	unless renewed.	
28		1
		I (CVS PHARMACY # 2994) ACCUSATION

1	JURISDICTION
2	3. This Accusation is brought before the Board under the authority of the following
3	laws. All section references are to the Business and Professions Code ("Code") unless otherwise
4	indicated.
5	4. Code section 118 states, in pertinent part:
6	
7	(b) The suspension, expiration, or forfeiture by operation of law of a license issued by a board in the department, or its suspension, forfeiture, or cancellation by
8	order of the board or by order of a court of law, or its surrender without the written consent of the board, shall not, during any period in which it may be renewed,
9 10	restored, reissued, or reinstated, deprive the board of its authority to institute or continue a disciplinary proceeding against the licensee upon any ground provided by law or to enter an order suspending or revoking the license or otherwise taking
11	disciplinary action against the licensee on any such ground.
12	
13	5. Code section 4011 states that the board shall administer and enforce this chapter and
14	the Uniform Controlled Substances Act (Division 1 (commencing with Section 11000) of the
15	Health and Safety Code).
16	6. Code section 4300 states, in pertinent part:
17	(a) Every license issued may be suspended or revoked.
18	(b) The board shall discipline the holder of any license issued by the board, whose default has been entered or whose case has been heard by the board and found guilty, by any of the following methods:
19 20	(1) Suspending judgment.
20	(2) Placing him or her upon probation.
21 22	(3) Suspending his or her right to practice for a period not exceeding one year.
23	(4) Revoking his or her license.
24	(5) Taking any other action in relation to disciplining him or her as the board in its discretion may deem proper
25	7. Code section 4300.1 states:
26	The expiration, cancellation, forfeiture, or suspension of a board-issued license by operation of law or by order or decision of the board or a court of law, the placement of a
27 28	license on a retired status, or the voluntary surrender of a license by a licensee shall not deprive the board of jurisdiction to commence or proceed with any investigation of, or
	2
	( CVS PHARMACY # 2994) ACCUSATION

1	action or disciplinary proceeding against, the licensee or to render a decision suspending or revoking the license.
2	8. Code section 4301 states, in pertinent part:
3	The board shall take action against any holder of a license who is guilty
4	of unprofessional conduct or whose license has been procured by fraud or misrepresentation or issued by mistake. Unprofessional conduct shall include, but is
5	not limited to, any of the following:
6	(j) The violation of any of the statutes of this state, of any other state,
7	or of the United States regulating controlled substances and dangerous drugs.
8	
9	(o) Violating or attempting to violate, directly or indirectly, or assisting in or abetting the violation of or conspiring to violate any provision or term of this chapter
10 11	or of the applicable federal and state laws and regulations governing pharmacy, including regulations established by the board or by any other state or federal regulatory agency.
12	
13	0 Collared time $4207$ (c) states in martinearty
14	9. Code section 4307 (a) states in pertinent part:
15	Any person who has been denied a license or whose license has been revoked or is under suspension, or who has failed to renew his or her license while it was under
16	suspension, or who has been a manager, administrator, owner, member, officer, director, associate, partner, or any other person with management or control of any partnership,
17	corporation, trust, firm, or association whose application for a license has been denied or revoked, is under suspension or has been placed on probation, and while acting as the
18	manager, administrator, owner, member, officer, director, associate, partner, or any other
19	person with management or control had knowledge of or knowingly participated in any conduct for which the license was denied, revoked, suspended, or placed on probation,
20	shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, partner, or in any other position with management or control of a
21	licensee as follows:
22	(1) Where a probationary license is issued or where an existing license is issued
23	or where an existing license is placed on probation, this prohibition shall remain in effect for a period not to exceed five years.
24	(2) Where the license is denied or revoked, the prohibition shall continue until
25	the license is issued or reinstated.
26	
27	///
28	
	3
	( CVS PHARMACY # 2994) ACCUSATION

1	STATUTORY AND REGULATORY PROVISIONS
2	10. Code section 4081 states, in pertinent part:
3	(a) All records of manufacture and of sale, acquisition, receipt, shipment, or disposition of dangerous drugs or dangerous devices shall be at all times during business
4	hours open to inspection by authorized officers of the law, and shall be preserved for at
5	least three years from the date of making. A current inventory shall be kept by every pharmacy who maintains a stock of dangerous drugs or dangerous devices.
6	
7	
8	11. Title 16, California Code of Regulations ("CCR"), section 1714 states, in pertinent
9	part:
10	
11	"(b) Each pharmacy licensed by the board shall maintain its facilities, space,
11	fixtures, and equipment so that drugs are safely and properly prepared, maintained, secured and distributed. The pharmacy shall be sufficient size and unobstructed area to
12	accommodate the safe practice of pharmacy."
13	
14	12. CCR section 1718 states:
16 17	"Current inventory" as used in Sections 4081 and 4332 of the Business and Professions Code shall be considered to include complete accountability for all dangerous drugs
17	handled by every licensee enumerated in Section 4081 and 4332. The controlled substances inventories required by Title 21, CFR, Section 1304 shall be available for inspection upon request
18	for at least 3 years after the date of the inventory.
19	13. Title 21, Code of Federal Regulations ("CFR"), part 1308, Section 14 (21 CFR
20	1308.14) states in pertinent part:
21	(a) Schedule IV shall consist of the drugs and other substances, by whatever
22	official name, common or usual name, chemical name, or brand name designated, listed in this section.
23	
24	(c) Depressants. Unless specifically excepted or unless listed in another
25	schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the
26	existence of such salts, isomers, and slats of isomers, and salts of isomers is possible within the specific chemical designation:
27	····
28	(6) Carisoprodol.
	4
	( CVS PHARMACY # 2994) ACCUSATION

1	14. Title 21	I, United States Cod	e, Section 802 state	es in pertinent part:	
2		6) The term "contro		-	ubstance, or
3	immediate pr	ecursor included in	schedule I, II, III, I	V, or V.	
4					
5		<u>(</u>	COST RECOVER	<u>Y</u>	
6	15. Code so	ection 125.3 provide	s, in pertinent part,	that a Board may re	quest the
7 °	administrative law	judge to direct a lice	entiate found to have	e committed a violat	tion or violations of
8 9	the licensing act to	pay a sum not to exe	ceed the reasonable	costs of the investig	gation and
10	enforcement of the	case.			
10			<u>G CLASSIFICAT</u>	<u>IONS</u>	
12	16. Drug C	lassifications:			
13			Dangerous	Controlled	
14 15	Brand Name	Generic Name	Drug Per Business & Professions	Substance Per Health & Safety Code	Indications for Use
16 17 18	Soma	carisoprodol	Code § 4022 Yes	No – per H&S Yes – Schedule IV per CFR §1308.14(c)(6)	Muscle relaxant
19	///				
19 20	/// ///				
20 21 22	///				
<ul><li>20</li><li>21</li><li>22</li><li>23</li></ul>	/// ///				
<ol> <li>20</li> <li>21</li> <li>22</li> <li>23</li> <li>24</li> </ol>	/// /// /// ///				
<ol> <li>20</li> <li>21</li> <li>22</li> <li>23</li> <li>24</li> <li>25</li> </ol>	/// /// /// ///				
<ol> <li>20</li> <li>21</li> <li>22</li> <li>23</li> <li>24</li> <li>25</li> <li>26</li> </ol>	<ul> <li>///</li> <li>///</li> <li>///</li> <li>///</li> <li>///</li> <li>///</li> <li>///</li> <li>///</li> <li>///</li> </ul>				
<ol> <li>20</li> <li>21</li> <li>22</li> <li>23</li> <li>24</li> <li>25</li> </ol>	<ul> <li>///</li> <li>///</li> <li>///</li> <li>///</li> <li>///</li> <li>///</li> <li>///</li> <li>///</li> </ul>				
<ol> <li>20</li> <li>21</li> <li>22</li> <li>23</li> <li>24</li> <li>25</li> <li>26</li> <li>27</li> </ol>	<ul> <li>///</li> <li>///</li> <li>///</li> <li>///</li> <li>///</li> <li>///</li> <li>///</li> <li>///</li> <li>///</li> </ul>		5		

1	STATEMENT OF FACTS
2	17. On or about August 10, 2018, the Board received notification from CVS Health <sup>1</sup> that
3	an investigation into employee drug diversion revealed that Nathan Lytle-Pinhey <sup>2</sup> a "floating"
4	Pharmacy Technician who worked at various CVS Pharmacies on an "as needed" basis, admitted
5	to diverting for self-use about 850 pills of carisoprodol 350 mg from Respondent and other CVS
6	pharmacies he floated at. Included in the notification was Respondent's Report of Theft or Loss
7	of Controlled Substances (DEA Form 106), which revealed a loss of 1,437 tablets of carisoprodol
8	350 mg ("drug loss").
9	18. On or about September 28, 2018, a Board Inspector conducted an investigation into
10	Respondent's drug loss. The Inspector reviewed Respondent's audit documents of the drug loss
11	between May 1, 2017 and July 5, 2018, and Respondent's Report of Theft or Loss of Controlled
12	Substances (DEA Form 106). As a result, the investigation found that Respondent failed to
13	adequately secure its drug stock, a violation of pharmacy law.
14	FIRST CAUSE FOR DISCIPLINE
15	(Failure to Secure and Maintain Pharmacy Facilities)
16	19. Respondent is subject to disciplinary action under Code section 4301, subdivisions (j)
17	and (o), in conjunction with California Code of Regulations title 16, section 1714, subdivision
18	(b), in that Respondent failed to maintain its facilities, space, fixtures, and equipment so that
19	drugs in its stock were safely maintained and secured. An investigation, subsequent to a report of
19 20 21	drugs in its stock were safely maintained and secured. An investigation, subsequent to a report of
20	drugs in its stock were safely maintained and secured. An investigation, subsequent to a report of employee diversion, found that between May 1, 2017 and July 5, 2018, Respondent failed to
20 21	drugs in its stock were safely maintained and secured. An investigation, subsequent to a report of employee diversion, found that between May 1, 2017 and July 5, 2018, Respondent failed to $\frac{1}{1}$ CVS Health Corporation is an integrated pharmacy healthcare company whose subsidiaries are the CVS Pharmacy stores, including Respondent.
20 21 22	drugs in its stock were safely maintained and secured. An investigation, subsequent to a report of employee diversion, found that between May 1, 2017 and July 5, 2018, Respondent failed to <sup>1</sup> CVS Health Corporation is an integrated pharmacy healthcare company whose subsidiaries are the CVS Pharmacy stores, including Respondent. <sup>2</sup> In an investigation into the drug losses, CVS Pharmacy Technician Nathan Lytle-Pinhey admitted to CVS District Asset Protection Leader, C.M., that while working as a Pharmacy
<ul><li>20</li><li>21</li><li>22</li><li>23</li></ul>	drugs in its stock were safely maintained and secured. An investigation, subsequent to a report of employee diversion, found that between May 1, 2017 and July 5, 2018, Respondent failed to <sup>1</sup> CVS Health Corporation is an integrated pharmacy healthcare company whose subsidiaries are the CVS Pharmacy stores, including Respondent. <sup>2</sup> In an investigation into the drug losses, CVS Pharmacy Technician Nathan Lytle-Pinhey admitted to CVS District Asset Protection Leader, C.M., that while working as a Pharmacy Technician at various CVS Pharmacies, he diverted 850 tablets of carisoprodol 350mg for self-use from CVS Pharmacies in Riverbank and in Turlock for approximately 6-7 months prior to
<ul> <li>20</li> <li>21</li> <li>22</li> <li>23</li> <li>24</li> </ul>	drugs in its stock were safely maintained and secured. An investigation, subsequent to a report of employee diversion, found that between May 1, 2017 and July 5, 2018, Respondent failed to <sup>1</sup> CVS Health Corporation is an integrated pharmacy healthcare company whose subsidiaries are the CVS Pharmacy stores, including Respondent. <sup>2</sup> In an investigation into the drug losses, CVS Pharmacy Technician Nathan Lytle-Pinhey admitted to CVS District Asset Protection Leader, C.M., that while working as a Pharmacy Technician at various CVS Pharmacies, he diverted 850 tablets of carisoprodol 350mg for self-use from CVS Pharmacies in Riverbank and in Turlock for approximately 6-7 months prior to July 2018. He also admitted that he was able to divert the drugs in his pockets and bags at "chaotic stores/work environments", "pharmacies being very busy", and at pharmacies that were
<ul> <li>20</li> <li>21</li> <li>22</li> <li>23</li> <li>24</li> <li>25</li> </ul>	drugs in its stock were safely maintained and secured. An investigation, subsequent to a report of employee diversion, found that between May 1, 2017 and July 5, 2018, Respondent failed to <sup>1</sup> CVS Health Corporation is an integrated pharmacy healthcare company whose subsidiaries are the CVS Pharmacy stores, including Respondent. <sup>2</sup> In an investigation into the drug losses, CVS Pharmacy Technician Nathan Lytle-Pinhey admitted to CVS District Asset Protection Leader, C.M., that while working as a Pharmacy Technician at various CVS Pharmacies, he diverted 850 tablets of carisoprodol 350mg for self-use from CVS Pharmacies in Riverbank and in Turlock for approximately 6-7 months prior to July 2018. He also admitted that he was able to divert the drugs in his pockets and bags at "chaotic stores/work environments", "pharmacies being very busy", and at pharmacies that were "2-3 days behind in workload". At the conclusion of the investigation, he was terminated from CVS. Pursuant to a stipulation with the Board, he has since surrendered his pharmacy technician
<ol> <li>20</li> <li>21</li> <li>22</li> <li>23</li> <li>24</li> <li>25</li> <li>26</li> </ol>	drugs in its stock were safely maintained and secured. An investigation, subsequent to a report of employee diversion, found that between May 1, 2017 and July 5, 2018, Respondent failed to <sup>1</sup> CVS Health Corporation is an integrated pharmacy healthcare company whose subsidiaries are the CVS Pharmacy stores, including Respondent. <sup>2</sup> In an investigation into the drug losses, CVS Pharmacy Technician Nathan Lytle-Pinhey admitted to CVS District Asset Protection Leader, C.M., that while working as a Pharmacy Technician at various CVS Pharmacies, he diverted 850 tablets of carisoprodol 350mg for self-use from CVS Pharmacies in Riverbank and in Turlock for approximately 6-7 months prior to July 2018. He also admitted that he was able to divert the drugs in his pockets and bags at "chaotic stores/work environments", "pharmacies being very busy", and at pharmacies that were "2-3 days behind in workload". At the conclusion of the investigation, he was terminated from
<ol> <li>20</li> <li>21</li> <li>22</li> <li>23</li> <li>24</li> <li>25</li> <li>26</li> <li>27</li> </ol>	drugs in its stock were safely maintained and secured. An investigation, subsequent to a report of employee diversion, found that between May 1, 2017 and July 5, 2018, Respondent failed to <sup>1</sup> CVS Health Corporation is an integrated pharmacy healthcare company whose subsidiaries are the CVS Pharmacy stores, including Respondent. <sup>2</sup> In an investigation into the drug losses, CVS Pharmacy Technician Nathan Lytle-Pinhey admitted to CVS District Asset Protection Leader, C.M., that while working as a Pharmacy Technician at various CVS Pharmacies, he diverted 850 tablets of carisoprodol 350mg for self-use from CVS Pharmacies in Riverbank and in Turlock for approximately 6-7 months prior to July 2018. He also admitted that he was able to divert the drugs in his pockets and bags at "chaotic stores/work environments", "pharmacies being very busy", and at pharmacies that were "2-3 days behind in workload". At the conclusion of the investigation, he was terminated from CVS. Pursuant to a stipulation with the Board, he has since surrendered his pharmacy technician

1	secure and maintain pharmacy facilities from diversion, theft, or other lapses which resulted in			
2	the drug loss set forth in paragraphs 17-18.			
3	SECOND CAUSE FOR DISCIPLINE			
4	(Failure to Maintain Accurate Inventory of Dangerous Drugs and Controlled Substances)			
5	20. Respondent is subject to disciplinary action under Code section 4301, subdivisions (j)			
5	and (o), in conjunction with Code sections 4081, subdivision (a), and 4105, in that it failed to			
,	maintain an accurate inventory of dangerous drugs and controlled substances. Specifically,			
3	during the above-mentioned investigation, Respondent provided a final reconciliation of the drug			
)	loss, which revealed a lesser amount in stock than was accounted for by records required by law,			
)	as set forth in paragraphs 17-18.			
	MATTERS IN AGGRAVATION			
2	21. To determine the degree of discipline, if any, to be imposed on Respondent,			
3	Complainant alleges:			
	a. On or about December 14, 2017, the Board issued Citation Number CI 2015 $66257^3$			
4 5	to Respondent for a violation of CCR, Title 16, Section 1716 (Deviation from Prescription			
5	Requirements).			
	b. On or about June 12, 2018, the Board issued a Citation and Fine Number			
7 3	CI 2017 76301 <sup>4</sup> to Respondent for violations of Business & Professions Code section 4105(a) /			
	Business & Professions Code section 4081(a) / Business & Professions Code section 4332 /			
)	Health & Safety Code section 11179 (\$800 Fine) (Failure to Maintain and Produce Original			
)	Prescription Documents As Required), and Health & Safety Code section 11164(a) / CCR title			
	16, section 1761(a)(b) (\$1,900 Fine) (Dispensed Controlled Substances With Improper			
2	Prescription Documents).			
3	OTHER MATTERS			
	22. Pursuant to Code section 4307, if discipline is imposed on Original Permit Number			
5	PHY 50132 to Garfield Beach CVS, LLC, to do business as CVS Pharmacy # 2994, Garfield			
	Beach CVS, LLC, shall be prohibited from serving as a manager, administrator, owner, member,			
	<sup>3</sup> Board records indicate that this citation has been completed. <sup>4</sup> Board records indicate that this citation has been paid.			
	7			
	( CVS PHARMACY # 2994) ACCUSATION			

1	officer, director, associate, or partner of a licensee for five years if Original Permit Number PHY			
2	50132 is placed on probation or until Original Permit Number PHY 50132 is reinstated if it is			
3	revoked.			
4	PRAYER			
5	WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged,			
6	and that following the hearing, the Board of Pharmacy issue a decision:			
7	1. Revoking or suspending Original Permit Number PHY 50132, issued to Garfield			
8	Beach CVS, LLC, to do business as CVS Pharmacy # 2994;			
9	2. Prohibiting Garfield Beach CVS, LLC, from serving as a manager, administrator,			
10	owner, member, officer, director, associate, or partner of a licensee for five years if Original			
11	Permit Number PHY 50132 is placed on probation or until Original Permit Number PHY 50132			
12	is reinstated if Original Permit Number PHY 50132 issued to Garfield Beach CVS, LLC, is			
13	revoked;			
14	3.	Ordering Respondent to pay the Be	oard of Pharmacy the reasonable costs of the	
15	investigation and enforcement of this case, pursuant to Business and Professions Code section			
16	125.3; and			
17	4.	4. Taking such other and further action as deemed necessary and proper.		
18		/		
19	DATED:	October 31, 2019	Inne Jodergren NNE SODERGREN	
20		Ir	nterim Executive Officer	
21		D	board of Pharmacy Department of Consumer Affairs tate of California	
22			Complainant	
23				
24				
25				
26				
27				
28				
	 		8	
			( CVS PHARMACY # 2994) ACCUSATION	